Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study

Clinical Gastroenterology and Hepatology(2021)10.1016/j.cgh.2021.03.031Source: DataRank Database

Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study is a research paper published in Clinical Gastroenterology and Hepatology (2021). On theSindex it has a DataRank of 0. It has been cited 36 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access36 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 3.98)OA: hybridTopics (21)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Marina Serper ORCID,Vandana Khungar ORCID,Laurence Weiss ORCID,Huy N. Trinh,Roberto Firpi-Morell

Live enrichment

PubMed:33775894 PMC:PMC8464616 OpenAlex:https://openalex.org/W3147609187

National Institutes of Health

Grant: 1K23DK1158907-03

NCATS NIH HHS

Grant: UL1 TR001863

NIDDK NIH HHS

Grant: K23 DK115897

Novo Nordisk

Inventiva Pharma

Intercept Pharmaceuticals

Sanofi

Novartis

Eli Lilly and Company

Gilead Sciences

Servier

Boehringer Ingelheim

FWCI

3.98

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.cgh.2021.03.031

publisherhttps://doi.org/10.1016/j.cgh.2021.03.031

publisherhttps://api.elsevier.com/content/article/PII:S1542356521003414?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1542356521003414?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33775894

Fields of Study

Liver Disease Diagnosis and TreatmentLipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

MeSH Terms

HumansLiver CirrhosisLiver NeoplasmsPrevalenceHydroxymethylglutaryl-CoA Reductase InhibitorsNon-alcoholic Fatty Liver Disease

Keywords

MedicineNonalcoholic fatty liver diseaseInternal medicineStatinCirrhosisGastroenterologyHepatocellular carcinomaFatty liverLiver diseaseChronic liver diseaseDiseaseDecompensation

Sustainable Development Goals

SDG 0: Good health and well-being

Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study

FAIR Checklist

Authors (14)

Funding (12 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)